Text Size

Indocyangreen Elimination in Cirrhosis and Acute Liver Failure

This study has been completed.
Sponsor:
Information provided by:
University of Heidelberg
ClinicalTrials.gov Identifier:
NCT00245310
First received: October 25, 2005
Last updated: October 8, 2010
Last verified: November 2008
History of Changes
  Purpose

Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion.

The ICG-clearance will be evaluated as a prognostic marker in liver disease.


Condition Intervention
Acute Liver Failure
Liver Cirrhosis
 Procedure: Indocyangreen (ICG) clearance

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure

Resource links provided by NLM:

MedlinePlus related topics: Cirrhosis
U.S. FDA Resources

Further study details as provided by University of Heidelberg:

Estimated Enrollment: 40
Study Start Date: October 2005
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Detailed Description:

patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

.

Criteria

Inclusion Criteria:

  • acute liver failure OR end-stage liver disease
  • normal hepatic perfusion by doppler ultrasound

Exclusion Criteria:

  • portal vein thrombosis
  • allergy to ICG or iodine
  • thyroid disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00245310

Locations
Germany
University of Heidelberg
Heidelberg, Germany, 69120
Sponsors and Collaborators
University of Heidelberg
Investigators
Principal Investigator: Jens Encke, PD Dr. med. University of Heidelberg
  More Information

No publications provided by University of Heidelberg

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00245310     History of Changes
Other Study ID Numbers: LiMON
Study First Received: October 25, 2005
Last Updated: October 8, 2010
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University of Heidelberg:
ICG clearance
liver cirrhosis
acute liver failure
prognosis

Additional relevant MeSH terms:
Liver Cirrhosis
Fibrosis
Liver Failure
Liver Failure, Acute
 Liver Diseases
Digestive System Diseases
Pathologic Processes
Hepatic Insufficiency

ClinicalTrials.gov processed this record on May 19, 2013